Skip to main content
Clinical Trials/JPRN-jRCTs042230090
JPRN-jRCTs042230090
Recruiting
Phase 1

Study on the effects of standing and walking practice using WPAL (Wearable Power-Assist Locomotor) on the quality of life and the secondary health conditions of people with spinal cord injury

Otaka Yohei0 sites30 target enrollmentOctober 17, 2023

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Spinal cord injury patients who fall into the subacute or maintenance phase
Sponsor
Otaka Yohei
Enrollment
30
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 17, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Otaka Yohei

Eligibility Criteria

Inclusion Criteria

  • 1\. Who have obtained written consent to participate in this study from the individual or his/her proxy or surrogate.
  • 2\. Whose age is between 16 and 80 years old.
  • 3\. Spinal cord injury patients undergoing WPAL in the subacute and maintenance phases. (Includes paraplegics and quadriplegics due to myelitis or spinal cord infarction. Also included are those who have already undergone WPAL.)
  • 4\. Who are between 155 cm and 180 cm in height.
  • 5\. Weighs less than 80 kg.

Exclusion Criteria

  • 1\. People with acute spinal cord injury.
  • 2\. Patients with dementia and impaired consciousness who have difficulty communicating.
  • 3\. Patients with easily fractured vertebrae and extremities.
  • 4\. Patients with significant contractures or heterotopic ossification of the spine or limbs.
  • 5\. Patients with pressure ulcers that interfere with robotic application.
  • 6\. Patients with cardiovascular or respiratory disease that makes exercise therapy difficult.
  • 7\. Patients with uncontrolled hypertension.
  • 8\. Pregnant patients or patients who may be pregnant.
  • 9\. Who have an infectious disease that requires isolation.
  • 10\. Patients with urinary or fecal incontinence to the extent that the WPAL is contaminated.

Outcomes

Primary Outcomes

Not specified

Similar Trials